Denali Therapeutics Management
Management criteria checks 3/4
Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $7.88M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.56% of the company’s shares, worth R$318.43M. The average tenure of the management team and the board of directors is 5.8 years and 8.1 years respectively.
Key information
Ryan Watts
Chief executive officer
US$7.9m
Total compensation
CEO salary percentage | 8.5% |
CEO tenure | 9.3yrs |
CEO ownership | 1.6% |
Management average tenure | 5.8yrs |
Board average tenure | 8.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$427m |
Jun 30 2024 | n/a | n/a | -US$420m |
Mar 31 2024 | n/a | n/a | -US$137m |
Dec 31 2023 | US$8m | US$670k | -US$145m |
Sep 30 2023 | n/a | n/a | -US$124m |
Jun 30 2023 | n/a | n/a | -US$128m |
Mar 31 2023 | n/a | n/a | -US$371m |
Dec 31 2022 | US$9m | US$645k | -US$326m |
Sep 30 2022 | n/a | n/a | -US$303m |
Jun 30 2022 | n/a | n/a | -US$284m |
Mar 31 2022 | n/a | n/a | -US$286m |
Dec 31 2021 | US$13m | US$610k | -US$291m |
Sep 30 2021 | n/a | n/a | US$30m |
Jun 30 2021 | n/a | n/a | US$56m |
Mar 31 2021 | n/a | n/a | US$58m |
Dec 31 2020 | US$9m | US$589k | US$71m |
Sep 30 2020 | n/a | n/a | -US$228m |
Jun 30 2020 | n/a | n/a | -US$216m |
Mar 31 2020 | n/a | n/a | -US$215m |
Dec 31 2019 | US$5m | US$567k | -US$198m |
Sep 30 2019 | n/a | n/a | -US$66m |
Jun 30 2019 | n/a | n/a | -US$55m |
Mar 31 2019 | n/a | n/a | -US$52m |
Dec 31 2018 | US$6m | US$545k | -US$36m |
Sep 30 2018 | n/a | n/a | -US$137m |
Jun 30 2018 | n/a | n/a | -US$123m |
Mar 31 2018 | n/a | n/a | -US$91m |
Dec 31 2017 | US$1m | US$481k | -US$88m |
Compensation vs Market: Ryan's total compensation ($USD7.88M) is above average for companies of similar size in the BR market ($USD1.26M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Watts (48 yo)
9.3yrs
Tenure
US$7,879,267
Compensation
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 9.3yrs | US$7.88m | 1.56% R$ 318.4m | |
Co-Founder | 9.7yrs | US$4.17m | 0.41% R$ 82.8m | |
Co-Founder & Independent Director | no data | US$431.93k | 1.47% R$ 300.0m | |
Chief Medical Officer & Head of Development | 9.4yrs | US$4.17m | 0.14% R$ 29.6m | |
Senior Vice President of Corporate Finance | no data | no data | no data | |
Chief Technical and Manufacturing Officer | 6.3yrs | no data | no data | |
Chief Scientific Officer | 4.3yrs | no data | no data | |
Vice President of Investor Relations | 4.8yrs | no data | no data | |
General Counsel | 5.8yrs | no data | no data | |
Vice President of Corporate Development | 1.8yrs | no data | no data | |
Chief People Officer | no data | no data | no data | |
Chief Commercial Officer | 3.2yrs | no data | no data |
5.8yrs
Average Tenure
51yo
Average Age
Experienced Management: D2NL34's management team is seasoned and experienced (5.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 9.7yrs | US$7.88m | 1.56% R$ 318.4m | |
Co-Founder & Independent Director | 9.7yrs | US$431.93k | 1.47% R$ 300.0m | |
Independent Chairperson | 9.6yrs | US$459.43k | 0.073% R$ 14.9m | |
Independent Director | 9.6yrs | US$444.43k | 0.24% R$ 48.4m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 9.6yrs | US$439.43k | 0.042% R$ 8.6m | |
Member of Scientific Advisory Board | 4yrs | no data | no data | |
Independent Director | 6.7yrs | US$439.43k | 0.011% R$ 2.2m | |
Independent Director | 6yrs | US$429.43k | 0.0098% R$ 2.0m | |
Director | 2.5yrs | US$419.43k | 0.57% R$ 117.6m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | 3.8yrs | no data | no data |
8.1yrs
Average Tenure
64yo
Average Age
Experienced Board: D2NL34's board of directors are considered experienced (8.1 years average tenure).